B cell subsets are associated with durable responses in distinct cancer types after immune checkpoint inhibition.

Sci Transl MedOct 28, 2026 (epub)

Sangwoo Shawn Kim, Sayuri Miyauchi, Riley N Jones et al.

✦ AI-curated · Sources linked

In 30 seconds

This study examined B-cell responses and outcomes after immune checkpoint inhibition, combining a prospective randomized phase 2 trial of 106 patients with single-cell profiling of intratumoral B cells from 152 patients across 12 tumor types. Antibody responses were associated with exceptional complete responses in certain cancer types. B-cell subsets showed context-dependent associations: germinal center and memory B cells were enriched in favorable-prognosis cohorts, whereas immunoglobulin A-positive plasma cells were enriched in unfavorable-prognosis cohorts. The findings also linked B cells with long-term survival, including among patients with high T-cell infiltration.

Key findings

  • In the prospective randomized phase 2 trial of 106 patients, B-cell antibody responses were associated with exceptional complete responses to immune checkpoint inhibitors in certain cancer types.
  • Across 12 tumor types, germinal center and memory B cells were enriched in favorable-prognosis cohorts, while immunoglobulin A-positive plasma cells were enriched in unfavorable-prognosis cohorts.
  • B cells were associated with improved long-term overall survival even when T-cell infiltrates were already high.
  • Rituximab depletion of B cells before surgery affected intratumoral T-cell frequency and diversity.

Why it matters

The findings suggest that adaptive antitumor immunity may involve coordinated B-cell and T-cell responses, and that the prognostic relevance of B cells depends on their subtype and tumor context. This broadens the assessment of immune responses associated with durable control beyond T-cell infiltration alone, while underscoring that B-cell effects should not be assumed to be uniformly favorable across cancers.

What to keep in mind

The reported associations vary by cancer type and do not establish that B-cell responses cause durable outcomes. The abstract does not provide quantitative effect estimates for the survival or response associations.

Source

Published in Sci Transl Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.